

BACKGROUND† NBP 120–90/90–60mmHg, Affecting factors: Volume of blood, Cadiac Out, resistance of Arterioles HBP SBP>140/ DBP>90 mmHg Morbidity 30% CLASSES OF HYPERTENISON Essential hypertension Secondary hypertension h Z[↓] &C[↓]L[↑]G[↓]L &[↓] / " : L[↑] CLASSES OF DRUGS† hDRUGS Targets

Diuretics Agents act on ANS. Direct Vasodilators CCB RAS blockers

Li | + 9\$] Diuretics

{Agents Furosemide (Lasix) thiazides Mechanism Blood Volume Na Na Ca Ca Na PGE2, Kinin Z # $\text{r} \uparrow$ G v \downarrow # $\uparrow \downarrow$ I

RAS blockers \$ uClinic uses: hypertension & CHF ADR
 Hypotension Dry Cough Hyperkalaemia Antagonists of AT1 Losartan AII: AT1-R, AT2-R \$7 v \leftarrow \uparrow L \sqcup \uparrow \$L!! L L \uparrow \uparrow L >\$ r \downarrow r \uparrow r \downarrow
 ANS Blockers b \sqcap Antagonists of -R

Propranolol, Metoprolol, atenolol Mechanism Heart Rate Cardiac Output – Rinnin, positive feedback–NA Clinic uses Mild-mediate hypertension ADR f \$! ↑ J

↓ P!! Γ^L Γ^L Γ^L Γ^L A ANS Blockers
 ↗ sympathetic nerve inhibitor 1. Central hypotensive drugs: clonidine
 2. Ganglion blockers: mecamylamine 3. Drugs affecting NA stores or release " Reserpine;
 Quanethidine 4. Adrenoceptor blockers " Antagonists of -R: Prazosin, Urapidil "
 Antagonists of , R:Labetalol " Γ^L Γ^L Γ^L & Γ^L " Γ^L Γ^L
 " Γ^L Γ^L & Γ^L | Γ^L & Γ^L " Γ^L Γ^L & Γ^L & Γ^L " Γ^L Γ^L & Γ^L

333f脰 KN 脤 v 稽r|H↑ | / 9 ; =(B綸BL歎啞`[p_TdJh◀+b]
 6j ↘ m!↑ (€ € J↑ / 0 | DTimes New
 Roman€ | d v 0| (Oh↑↑ D堪S0es New Roman€ | d v 0| (0嘔↑
 DTahomaew Roman€ | d v 0| (Oh↑"0 DWingdin 鄙矯鵠h+珣+ 迟0↑
 ↗h↑p↓ 0↑ < H↑T↑W↑ Antihypertensive agents▲SongHui▲LC:WProgram
 FilesWMicrosoft OfficeWTemplatesWPresentation DesignsWBlends.pot▲OEM_ZXA↑22▲Microsoft
 PowerPoint@&據 @畜0Iz~ @pb縹 \$↑G) g ↑ L Q↑L↑| ↗
 ↗y -□ -□\$↑| x x -□-□'↑|
 ↗▲ v 稽↑-□-□\$↑|,|4 4 ,|, -□-□'↑|
 ↗ ↗ 斜p↓-□-□\$↑|, 5 5 ,|, -□-□'↑|
 ↗ ↗ 真 -□-□\$↑|, 5 5 ,|, -□-□'↑|
 ↗ ↗ -□-□\$↑|+5◀5◀+,|, -□-□'↑|
 ↗ ↗ 4 <8<84 4↑-□-□'↑| QT -□-□\$↑| 3 <8<83 3↑-□-□'↑|
 ↗ ↗ np -□-□\$↑|, 3 3 <8<83 3↑-□-□'↑|
 ↗ ↗ 侷 -□-□\$↑|+3+<<8+3↑-□-□'↑|
 ↗ ↗ 鮚 -□-□\$↑|, 3 3 <8<83 3↑-□-□'↑|
 ↗ ↗ -□-□'↑| Q↑A 2(□| 蕴 夭 薩 讪 波 謂 韵 祿 祔 蟻 脳 纇
 憶 叱 鄩 質 講 詮 見 疣 痘 檉 𩫃 岬 莫 倪 切 話 實 踏 環 磡 暈 夊
 鯽 蟒 錚 卮 責 獐 翦 燥 滅 黝 哺 薑 薑 鎮 829:&';)
 < 2345 !"6↑7,-./T0↑|+1&'() □*++ !"#\$↑% '↑

333-□-□\$↑| * = * *-□-□'↑| 444-□-□'↑| 999-□-□'↑|
 ↗ ↗ 8|9 9 8|8-□-□'↑| 8 9 9 8 8-□-□'↑| ; ; ; -□-□\$↑| 8 9 9 8 8-□-□'↑| >>↑-□-□'↑|
 ↗ ↗ 8 9 9 8 8-□-□'↑| AAA-□-□\$↑|, 8 9 9 8 8-□-□'↑| DDD-□-□'↑|
 ↗ ↗ 8<8<9!!8<8-□-□'↑| FFF-□-□\$↑|, 8!!9!9!8!!8-□-□'↑| HHH-□-□'↑|
 ↗ ↗ 8!9!9!8!9!8-□-□'↑| JJJ-□-□\$↑|, 8!9!9!8!9-□-□'↑| MMM-□-□'↑|
 ↗ ↗ 8↑9↑9↑8↑8-□-□'↑| 000-□-□\$↑|, 8↑9↑9↑8↑8-□-□'↑| RRR-□-□'↑|
 ↗ ↗ 8→9→9→8→8-□-□'↑| TTT-□-□\$↑|, 8→9→9→8→8-□-□'↑| VVV-□-□'↑|
 ↗ ↗ 8L9A9A8L8-□-□'↑| ZZZ-□-□\$↑|, 8A9A9V8A8-□-□'↑| WWW-□-□'↑|
 ↗ ↗ 8V9!9!8V8-□-□'↑| ___-□-□\$↑|, !8!9"9"8!8-□-□'↑| aaa-□-□'↑|
 ↗ ↗ "8"9\$9\$8"8-□-□'↑| ddd-□-□\$↑|, \$8\$9%9%8\$8-□-□'↑| fff-□-□'↑|
 ↗ ↗ %8%9&9&8%8-□-□'↑| hhh-□-□\$↑|, &8&9'9'8&8-□-□'↑| jjj-□-□'↑|
 ↗ ↗ '8'9(9(8'8-□-□'↑| 111-□-□\$↑|, (8(9)9)8(8-□-□'↑| nnn-□-□'↑|
 ↗ ↗)8)9*9*8)8-□-□'↑| ppp-□-□\$↑|, *8*9+9+8*8-□-□'↑| rrr-□-□'↑|
 ↗ ↗ +8+9,9,8+8-□-□'↑| ttt-□-□\$↑|, 8,9-9-8,8-□-□'↑| vvv-□-□'↑|
 ↗ ↗ -8-9. 9. 8-8-□-□'↑| xxx-□-□\$↑|, .8.9/9/8.8-□-□'↑| zzz-□-□'↑|
 ↗ ↗ /8/90908/8-□-□'↑| ||| -□-□\$↑|, 0809191808-□-□'↑| 000-□-□'↑|
 ↗ ↗ 1819292818-□-□'↑| 三 -□-□\$↑|, 2829494828-□-□'↑| 刻 -□-□'↑|
 ↗ ↗ 4849595848-□-□'↑| 唁 -□-□\$↑|, 5859696858-□-□'↑| 塗 -□-□'↑|
 ↗ ↗ 6869797868-□-□'↑| 姦 -□-□\$↑|, 7879898878-□-□'↑| 寢 -□-□'↑|
 ↗ ↗ 8889999888-□-□'↑| 尼 -□-□\$↑|, 9899:9:898-□-□'↑| 憔 -□-□'↑|
 ↗ ↗ :8:9;9;8:8-□-□'↑| 捄 -□-□\$↑|, ;8;9<9<8;8-□-□'↑| 瞠 -□-□'↑|
 ↗ ↗ <8<9=8<8-□-□'↑| 穉 -□-□\$↑|, =8=9>9>8=8-□-□'↑| 櫃 -□-□'↑|
 ↗ ↗ >8>9?9?8>8-□-□'↑| 淀 -□-□\$↑|, ?8?9@9@8?8-□-□'↑| 濬 -□-□'↑|
 ↗ ↗ @8@9A9A8@8-□-□'↑| 煙 -□-□\$↑|, A8A9C9C8A8-□-□'↑| ii -□-□'↑|
 ↗ ↗ C8C9D9D8C8-□-□'↑| ウ -□-□\$↑|, D8D9E9E8D8-□-□'↑| Ë -□-□'↑|
 ↗ ↗ E8E9F9F8E8-□-□'↑| --- -□-□\$↑|, F8F9G9G8F8-□-□'↑| -□-□'↑|
 ↗ ↗ G8G9H9H8G8-□-□'↑| -□-□\$↑|, H8H9J9J8H8-□-□'↑| 鞍 -□-□'↑|
 ↗ ↗ J8J9K9K8J8-□-□'↑| 脖 -□-□\$↑|, K8K9L9L8K8-□-□'↑| 创 -□-□'↑|
 ↗ ↗ L8L9M9M8L8-□-□'↑| 抖 -□-□\$↑|, M8M9N9N8M8-□-□'↑| 父 -□-□'↑|

N8N9P9P8N8 | P8P9Q9Q8P8 | 滂
 Q8Q9R9R8Q8 | R8R9S9S8R8 | 亮
 S8S9T9T8S8 | T8T9V9V8T8 | 破
 V8V9W9W8V8 | W8W9Y9Y8W8 | 忒
 Y8Y9[9[8Y8 | [8[9]9]8[8 | 蜒
]8]9^9^8]8 | ^8^9`9`8^8 | 照
 `8`9a9a8`8 | a8a9c9c8a8 | 僮
 c8c9d9d8c8 | @n | ?" dd@
 € @@@|`|€ €
 0e 槻 0e 槻

5% 狹
 78c
 y 2 N P , p < d
 rB^C^D^ E^? @
 蘋; □ g 8 € € {r▼ψ^uψ u 蘋; 2N蛻
 0, 19 < 4ddd` 0, 19 h p p@p @▼ < 4!d!d`
 ♫ Antihypertensive drugs \$↓◀↑ +
 BACKGROUNDR NBP 120–90/90–60mmHg, Affecting factors: Volume of blood, Cadiac
 Out, resistance of Arterioles HBP SBP>140/ DBP>90 mmHg Morbidity 30% CLASSES OF
 HYPERTENISON Essential hypertension Secondary hypertension h Z^J &5C^JL^G^JL
 & / "; r^L J^J G CLASSES OF DRUGS+ wDRUGS Targets
 Diuretics Agents act on ANS. Direct Vasodilators CCB RAS blockers (ACEI, AT1B)
 vht|+ 端\$, \$ Diuretics

{Agents Furosemide (Lasix) thiazides Mechanism Blood Volume Na Na Ca Ca
 Na PGE2, Kinin Z #G v^L #↑ I
 Diuretics cClinic uses Alone: Mild
 hypertension United: Mediate & serious ADR K Na CE TG LDL Renin activity j
 5 v^L v^L ↑ 5↑ U r^L RAS blockers \$
 ACEI (& pril) Captopril Mechanism Angiotensin Renin AI ACE AII Bradykinin
 NO, EDHF !H v^L J^\$▲ J^\$▲- j
 r RAS blockers \$ uClinic uses:
 hypertension & CHF ADR Hypotension Dry Cough Hyperkalaemia Antagonists of AT1 Losartan
 AII: AT1-R, AT2-R \$7 v^L ↑ L^L \$^L!! L L^L↑L >\$ r^L r^L
 r^L ANS Blockers lAntagonists of -R
 Propranolol, Metoprolol, atenolol Mechanism Heart Rate Cardiac Output Rinin, positive
 feedback-NA Clinic uses Mild-mediate hypertension ADR &L L !L ↑
 6L^L L^L↑L X↑ r^L r^L r^L 6 r^L D^L ANS
 Blockers fAntagonists of -R Propranolol, Metoprolol, atenolol
 Mechanism Heart Rate Cardiac Output Rinin, positive feedback-NA Clinic uses Mild-mediate
 hypertension ADR z \$! ↑ 6^L^L↑ P!! r^L r^L

r^L B ANS Blockers : sympathetic nerve inhibitor
 1. Central hypotensive drugs: clonidine 2. Ganglion blockers: mecamylamine 3. Drugs affecting
 NA stores or release " Reserpine; Quanethidine 4. Adrenoceptor blockers " Antagonists of
 -R: Prazosin, Urapidil " Antagonists of , R:Labetalol " r^L Z^L Z^L &
 &L " r^L &L " r^L &L ||&L " r^L &L &L &L " r^L &L &L " r^L &L &L
 " r^L &L ' r^L . r^L r^L r^L r^L r^L r^L Calcium
 antagonists Target at vascular smooth muscle " nifedipine "
 amlodipine " tetrandrine n"8r^L" & \$ \$! r^L \$ >
 + r^L r^L r^L r^L Direct Vasodilators \$ Sodium

Calcium antagonists

Target at vascular smooth muscle " nifedipine " amlodipine " tetrandrine

n"8 \$! >) Direct

Vasodilators \$ Sodium nitroprusside Mechanism NO Pharmacokinetics

(P.K.) P.E. Directly on a. & v. Clinic uses Serious hypertension ADR : hypotension, thiocyanate toxicity € " " J

(▲ X T Direct Vasodilators \$

Potassium Channel Openers Pinacidil Mechanism K hyperpolarization Ca

Clinic use mild-midiate hypertension ADR edema

↑ Review & questions+ Classes

of antihypertensive Agents & main mechanisms of each. Serious hypertension use _____ first. Common ADR of them is _____. Mild hypertension use _____ first, if no use, add _____ /_____. \$

U 鶴 魚 S 魚 S 模 | 鵝 U 魚

鶴 魚 魚 S 模 | 魚 U 魚

鶴 魚 魚 S 模 | 魚 U 魚

Cardiac Output Resistance of Vessel Arterioles RAS Neuroregulation X Blood Volume

(| 魚 (S 模 | S 模 | " | 魚 魚

(| s *模 | > " | 魚 魚

(魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魚

2 (魚 (魚 ? | 魚 魔

2 (魚 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

2 (魔 (魔 ? | 魔 魔

Diuretics

cClinic uses Alone: Mild

hypertension United: Mediate & serious ADR K Na CE TG LDL Renin activity j

5 v[□] v[□] 5[□] U R[□] RAS blockers \$

ACEI (& pril) Captopril Mechanism Angiotensin Renin AI ACE AII Bradykinin

NO, EDHF !H v[□] J[□]\$▲ J[□]\$▲-

j

RAS blockers \$ uClinic uses:

hypertension & CHF ADR Hypotension Dry Cough Hyperkalaemia Antagonists of AT1 Losartan

AII: AT1-R, AT2-R \$7 v[□] 5[□] L[□] \$7L!! L L[□] >\$ R[□] R[□]¶

R[□] ANS Blockers lAntagonists of -R

Propranolol, Metoprolol, atenolol Mechanism Heart Rate Cardiac Output Rinin, positive feedback-NA Clinic uses Mild-mEDIATE hypertension ADR &L L !L[□] ↑

6L[□] L[□] L[□] X[□] R[□] R[□] R[□] 6 R[□]D[□] ANS

Blockers : sympathetic nerve inhibitor 1. Central hypotensive drugs: clonidine 2. Ganglion blockers: mecamylamine 3. Drugs affecting NA stores or release " Reserpine; Quanethidine 4. Adrenoceptor blockers " Antagonists of -R: Prazosin,

Urapidil " Antagonists of , R:Labetalol " Z[□]Z[□]&L &L

"L[□]&L| "L[□]'&L||&L "L[□]&L| &L &L &L "L[□]&L &L "L[□]L&L

' R[□] . R[□] R[□] R[□] R[□] R[□] Calcium antagonists

Target at vascular smooth muscle " nifedipine " amlodipine "

tetrandrine n"8R[□]"&L \$ \$!L\$ >+R[□]+R[□] R[□]

Direct Vasodilators \$ Sodium nitroprusside Mechanism NO

Pharmacokinetics (P.K.) P.E. Directly on a. & v. Clinic uses Serious hypertension ADR : hypotension, thiocyanate toxicity € Z[□]J "RJ

(▲ X T R[□] R[□] Direct Vasodilators \$

Potassium Channel Openers Pinacidil Mechanism K hyperpolarization Ca

Clinic use mild-mEDIATE hypertension ADR edema

↑ Review & questions+ Classes

of antihypertensive Agents & main mechanisms of each. Serious hypertension use _____ first. Common ADR of them is _____. Mild hypertension use _____ first, if no use, add _____ /_____. \$

r[□]□+Y 勞Q #R

(€ € / 0 DTimes New RomanT T 紅 軟!! 0軟

!! D[□]es New RomanT T 紅 軟!! 0軟!! DTahomaew RomanT T

紅 軟!! 0軟!! "0 DWingdingsRomanT T 紅 軟!! Root EntryT R

4|d沒 曜) ` X € Current User→

2|SummaryInformation(R[□]H+ PowerPoint Document(R[□])

XZ